Group 1: Company Restructuring and Financial Status - The company signed a restructuring investment agreement on May 6, 2025, and the pre-restructuring work is progressing in an orderly manner [1] - The audited net assets attributable to the parent company for 2024 are negative, posing a risk of stock delisting [2] - If the restructuring is successful, it will significantly improve the company's financial status and reduce debt [3] Group 2: Stock Increase and Capital Structure - The company plans to increase its capital by converting 10 shares into 15 shares, resulting in a total share capital increase from 350,336,112 shares to 875,840,280 shares [2] - The conversion price is set at 2.42 CNY per share, with a total of 525,504,168 shares available for conversion [2] - Remaining shares after the restructuring will be used to repay ordinary creditors at a price not lower than 10 CNY per share [2] Group 3: Investor Relations and Market Concerns - The company is addressing investor concerns regarding stock price fluctuations influenced by various factors, including company performance and market conditions [2] - There is no current request from industry investors to change the company's main business [2] - The company has not received any consent letters from the China Securities Regulatory Commission regarding the restructuring [3] Group 4: Management and Operational Changes - If the restructuring is successful, the controlling shareholder will change to Sichuan Jiadaobowen Ecological Technology Co., Ltd. [3] - The new industry investors are expected to recommend talent to enhance the company's operational capabilities [4] - The company currently has no specific plans for its photovoltaic sector [3]
*ST长药(300391) - 300391*ST长药投资者关系管理信息20250509